We are proud of the clinical evidence, R&D achievements, our FDA’s breakthrough device designation for our pancreatic cancer test panel, and our  history has Bluestar Genomics. Now, as a commercial-stage company, ClearNote Health continues to drive innovation in non-invasive cancer detection, with patient needs at the core of everything we pursue. 

ClearNote Health is currently conducting  several clinical studies at multiple sites. Learn more about study design, patient criteria, and enrollment: 

• Clinical Validation of a Pancreatic Cancer Detection Test in New-Onset Diabetes Patients
• New Onset Diabetes Management for Earlier Detection of Pancreatic Cancer (NODMED)
• Surveillance of Pancreatic Health After Diabetes Diagnosis (SAFE-D)